These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30312106)

  • 21. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
    Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
    Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Portopulmonary hypertension.
    Barua UK; Hossain AS; Roy GC; Rahman MA; Das M
    Mymensingh Med J; 2013 Jul; 22(3):618-24. PubMed ID: 23982562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells.
    Yang J; Li X; Li Y; Southwood M; Ye L; Long L; Al-Lamki RS; Morrell NW
    Am J Physiol Lung Cell Mol Physiol; 2013 Aug; 305(4):L312-21. PubMed ID: 23771884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pulmonary hypertension in liver diseases].
    Savale L; Sattler C; Sitbon O
    Presse Med; 2014 Sep; 43(9):970-80. PubMed ID: 25148949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical aspects of portopulmonary hypertension.
    Medarov BI; Chopra A; Judson MA
    Respir Med; 2014 Jul; 108(7):943-54. PubMed ID: 24816204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children.
    Hodgson J; Ruiz-Llorente L; McDonald J; Quarrell O; Ugonna K; Bentham J; Mason R; Martin J; Moore D; Bergstrom K; Bayrak-Toydemir P; Wooderchak-Donahue W; Morrell NW; Condliffe R; Bernabeu C; Upton PD
    Mol Genet Genomic Med; 2021 Dec; 9(12):e1685. PubMed ID: 33834622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.
    Yamanaka R; Otsuka F; Nakamura K; Yamashita M; Otani H; Takeda M; Matsumoto Y; Kusano KF; Ito H; Makino H
    Hypertens Res; 2010 May; 33(5):435-45. PubMed ID: 20186146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience.
    Awdish RL; Cajigas HR
    Lung; 2013 Dec; 191(6):593-600. PubMed ID: 23979006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
    Yang J; Li X; Al-Lamki RS; Wu C; Weiss A; Berk J; Schermuly RT; Morrell NW
    Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):34-42. PubMed ID: 23139294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry.
    Sithamparanathan S; Nair A; Thirugnanasothy L; Coghlan JG; Condliffe R; Dimopoulos K; Elliot CA; Fisher AJ; Gaine S; Gibbs JSR; Gatzoulis MA; E Handler C; Howard LS; Johnson M; Kiely DG; Lordan JL; Peacock AJ; Pepke-Zaba J; Schreiber BE; Sheares KKK; Wort SJ; Corris PA;
    J Heart Lung Transplant; 2017 Jul; 36(7):770-779. PubMed ID: 28190786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Portopulmonary hypertension: survival and prognostic factors.
    Le Pavec J; Souza R; Herve P; Lebrec D; Savale L; Tcherakian C; Jaïs X; Yaïci A; Humbert M; Simonneau G; Sitbon O
    Am J Respir Crit Care Med; 2008 Sep; 178(6):637-43. PubMed ID: 18617641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease.
    Savale L; Manes A
    Eur Heart J Suppl; 2019 Dec; 21(Suppl K):K37-K45. PubMed ID: 31857799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
    Al-Naamani N; Krowka MJ; Forde KA; Krok KL; Feng R; Heresi GA; Dweik RA; Bartolome S; Bull TM; Roberts KE; Austin ED; Hemnes AR; Patel MJ; Oh JK; Lin G; Doyle MF; Denver N; Andrew R; MacLean MR; Fallon MB; Kawut SM;
    Hepatology; 2021 Feb; 73(2):726-737. PubMed ID: 32407592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Portopulmonary Hypertension and Liver Transplant: Recent Review of the Literature.
    Cosarderelioglu C; Cosar AM; Gurakar M; Pustavoitau A; Russell SD; Dagher NN; Gurakar A
    Exp Clin Transplant; 2016 Apr; 14(2):113-20. PubMed ID: 27015528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BMP9 and BMP10: Two close vascular quiescence partners that stand out.
    Desroches-Castan A; Tillet E; Bouvard C; Bailly S
    Dev Dyn; 2022 Jan; 251(1):178-197. PubMed ID: 34240497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Waitlist Mortality in Portopulmonary Hypertension.
    DuBrock HM; Goldberg DS; Sussman NL; Bartolome SD; Kadry Z; Salgia RJ; Mulligan DC; Kremers WK; Kawut SM; Krowka MJ; Channick RN
    Transplantation; 2017 Jul; 101(7):1609-1615. PubMed ID: 28207639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Portopulmonary hypertension.
    Mukhtar NA; Fix OK
    J Clin Gastroenterol; 2011 Sep; 45(8):703-10. PubMed ID: 21325952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristic haemodynamic changes of cirrhosis may influence the diagnosis of portopulmonary hypertension.
    Chiva T; Ripoll C; Sarnago F; Rincón D; Gómez-Camarero J; Galindo E; Catalina MV; Elizaga J; Bañares R
    Liver Int; 2015 Feb; 35(2):353-61. PubMed ID: 24797536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.
    Mitrofan CG; Appleby SL; Nash GB; Mallat Z; Chilvers ER; Upton PD; Morrell NW
    J Biol Chem; 2017 Aug; 292(33):13714-13726. PubMed ID: 28646109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of survival in portopulmonary hypertension: a 20-year experience.
    Aggarwal M; Li M; Bhardwaj A; Wallace WD; Wang X; Carey WD; Dweik RA; Heresi GA; Tonelli AR
    Eur J Gastroenterol Hepatol; 2022 Apr; 34(4):449-456. PubMed ID: 34907982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.